Polyionic Papillomavirus VLPs for Rapid Cytolytic T Cell Response
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for highly pathogenic coronaviruses like SARS-CoV-1, MERS, and SARS-CoV-2 lack effective antiviral drugs, and inducing a rapid cytotoxic T cell response is necessary to control acute infections before the host is overwhelmed.
Innovation Solution
A strategy involving polyionic papillomavirus virus-like particles (VLPs) with inserted negatively charged amino acids and fusion peptides/proteins is used to stimulate cross-reactive memory T cells, targeting both pathogenic and common cold coronaviruses to rapidly mobilize a cytolytic T cell response.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional antiviral treatments are used for highly pathogenic coronaviruses, then treatment is primarily supportive with no highly active anti-viral drugs, but the host becomes overwhelmed before immune response can develop
Solution Approach 1:
The patent applies preliminary action by pre-immunizing hosts with coronavirus antigens before challenge infection. This primes the immune system in advance so that when actual infection occurs, memory T cells are already present and can rapidly respond. The pre-immunization creates a reservoir of activated T cells that can immediately control viral replication upon exposure, eliminating the dangerous delay associated with de novo immune response development.
Solution Approach 2:
The patent employs parameter changes by modifying the timing and intensity of immune response activation. Through controlled pre-immunization regimens, the immune system is activated to a specific level of readiness before challenge. This adjusts the parameter of immune response speed and magnitude, ensuring that protective immunity is established without causing pathological pre-sensitization or excessive inflammation during actual infection.
2Reliability
If maximal T cell response is induced through immunization, then protective immunity is achieved, but weeks or months are required to achieve the response
Solution Approach 1:
The invention uses preliminary action by conducting pre-immunization with coronavirus antigens before the challenge infection occurs. This advance preparation creates memory T cells that persist in the host and can be rapidly reactivated upon exposure to the actual virus. The pre-established memory T cell pool eliminates the need for de novo T cell activation and differentiation, reducing the response time from weeks/months to days or hours.
Solution Approach 2:
The patent applies copying by using antigen preparations that replicate key epitopes and immunogenic structures of the actual coronavirus. The pre-immunization antigens are designed to mimic the viral proteins and epitopes that will be encountered during natural infection, creating T cell memory that is specific and functional against the real virus. This copying approach ensures that the memory response is appropriately targeted and effective.
3Speed
If cross-reactive memory T cells are stimulated, then rapid cytolytic T cell response is mobilized, but the strategy must target both pathogenic and common cold coronaviruses
Solution Approach 1:
The patent applies universality by designing antigen preparations that contain epitopes from multiple coronavirus types (pathogenic coronaviruses like SARS-CoV-1 and SARS-CoV-2, and common cold coronaviruses). This multi-functional antigen composition simultaneously targets several coronavirus lineages, exploiting the cross-reactivity of T cell memory. A single vaccine formulation provides broad protection across different coronavirus strains, eliminating the need for separate vaccines for each virus while maintaining rapid protective response.
Solution Approach 2:
The invention uses composite materials by combining multiple coronavirus antigens and epitopes into a single immunogen preparation. The composite antigen contains representative sequences from different coronavirus genera and species, creating a polyvalent vaccine that elicits cross-reactive T cell responses. This composite approach consolidates multiple protective targets into one formulation, simplifying delivery while achieving broad-spectrum immunity through the synergistic action of multiple antigen components.
Data Source
AI summary
Compositions and methods to induce cytolytic T lymphocytes (CD8+) response, that is, MHC class I restricted T cell responses, to pathogenic and common cold coronaviruses, including a delivery platform for antigens consisting of a polyionic papillomavirus virus-like particle (VLP), with contiguous, negatively charged amino acids flanked by a cysteine residue inserted in the HI loop of the papillomavirus L1 protein. Antigens to be paired with the VLP include fusion peptide/proteins derived from a pathogenic coronavirus, and from the genetically most closely related human coronaviruses that commonly circulate in human populations, with N-terminal or C-terminal amino acids consisting of contiguous, positively charged amino acids preceded and/or followed by a cysteine residue and a C-terminal proteolytic processing sequence (AAYY) to enhance presentation of MHC class I epitopes.